Trial Summary
CD22 CAR T-cell treatment is unique because it targets the CD22 protein on leukemia cells, which is often retained even when other targets like CD19 are lost, making it effective for patients who do not respond to CD19-targeted therapies. This treatment involves modifying a patient's own immune cells to better recognize and attack leukemia cells, offering a novel approach for those with resistant forms of the disease.
234711Research shows that CD22 CAR T Cells treatment can lead to remission in patients with acute lymphoblastic leukemia (ALL), especially those who did not respond to previous treatments targeting a different protein (CD19). In one study, 73% of patients achieved complete remission, although the remissions were often short-lived due to changes in the leukemia cells.
123611The trial protocol does not specify if you need to stop taking your current medications. However, you must meet a washout period (time without taking certain medications) since prior therapies according to commercial KYMRIAH® (tisagenlecleucel) guidelines.
CD22 CAR T-cell therapy has been studied in early phase trials and is generally considered safe, but it can cause side effects like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Severe cases of these side effects are rare, and the therapy's safety profile is similar to other CAR T-cell therapies.
578910Eligibility Criteria
This trial is for children and young adults with B-cell leukemia that has come back or hasn't responded to treatment. They must have already received a commercial CAR T cell therapy called tisagenlecleucel.Inclusion Criteria
Exclusion Criteria